These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1633 related items for PubMed ID: 31636098

  • 41. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8+ T-cell infiltration in hepatocellular carcinoma.
    Song F, Hu B, Liang XL, Cheng JW, Wang CG, Wang PX, Wang TL, Tang PJ, Sun HX, Guo W, Zhou J, Fan J, Chen Z, Yang XR.
    Clin Transl Med; 2024 Aug; 14(8):e1738. PubMed ID: 39095323
    [Abstract] [Full Text] [Related]

  • 42. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo.
    Wang XX, Wang QQ, Wu JQ, Jiang M, Chen L, Zhang CF, Xiang LH.
    Br J Dermatol; 2016 Jun; 174(6):1318-26. PubMed ID: 26801009
    [Abstract] [Full Text] [Related]

  • 43. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
    Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stöckel A, Avril S, Kiechle M, Schmitt M.
    Breast Cancer Res; 2012 Feb 14; 14(1):R30. PubMed ID: 22333315
    [Abstract] [Full Text] [Related]

  • 44. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
    Dammeijer F, Lau SP, van Eijck CHJ, van der Burg SH, Aerts JGJV.
    Cytokine Growth Factor Rev; 2017 Aug 14; 36():5-15. PubMed ID: 28693973
    [Abstract] [Full Text] [Related]

  • 45. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
    Kuo IY, Yang YE, Yang PS, Tsai YJ, Tzeng HT, Cheng HC, Kuo WT, Su WC, Chang CP, Wang YC.
    Theranostics; 2021 Aug 14; 11(14):7029-7044. PubMed ID: 34093869
    [Abstract] [Full Text] [Related]

  • 46. Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8+ T cell infiltration.
    Gan L, Lu T, Lu Y, Song H, Zhang J, Zhang K, Lu S, Wu X, Nie F, Di S, Han D, Yang F, Qin W, Wen W.
    J Immunother Cancer; 2024 Sep 10; 12(9):. PubMed ID: 39260826
    [Abstract] [Full Text] [Related]

  • 47. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
    Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM.
    J Immunol; 2015 Feb 01; 194(3):950-9. PubMed ID: 25539810
    [Abstract] [Full Text] [Related]

  • 48. GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models.
    Torphy RJ, Sun Y, Lin R, Caffrey-Carr A, Fujiwara Y, Ho F, Miller EN, McCarter MD, Lyons TR, Schulick RD, Kedl RM, Zhu Y.
    Nat Commun; 2022 Jan 10; 13(1):97. PubMed ID: 35013216
    [Abstract] [Full Text] [Related]

  • 49. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.
    Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P.
    Cancer Immunol Res; 2019 Nov 10; 7(11):1803-1812. PubMed ID: 31466995
    [Abstract] [Full Text] [Related]

  • 50. STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis.
    Yue C, Shen S, Deng J, Priceman SJ, Li W, Huang A, Yu H.
    Cancer Immunol Res; 2015 Aug 10; 3(8):864-870. PubMed ID: 26025380
    [Abstract] [Full Text] [Related]

  • 51. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
    Saha D, Martuza RL, Rabkin SD.
    Cancer Cell; 2017 Aug 14; 32(2):253-267.e5. PubMed ID: 28810147
    [Abstract] [Full Text] [Related]

  • 52. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade.
    Chen IX, Newcomer K, Pauken KE, Juneja VR, Naxerova K, Wu MW, Pinter M, Sen DR, Singer M, Sharpe AH, Jain RK.
    Proc Natl Acad Sci U S A; 2020 Sep 22; 117(38):23684-23694. PubMed ID: 32907939
    [Abstract] [Full Text] [Related]

  • 53. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM, Johnson CE, Williams CJ.
    Int Immunopharmacol; 2018 Sep 22; 62():29-39. PubMed ID: 29990692
    [Abstract] [Full Text] [Related]

  • 54. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
    Hensbergen PJ, Wijnands PG, Schreurs MW, Scheper RJ, Willemze R, Tensen CP.
    J Immunother; 2005 Sep 22; 28(4):343-51. PubMed ID: 16000952
    [Abstract] [Full Text] [Related]

  • 55. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
    Berghuis D, Santos SJ, Baelde HJ, Taminiau AH, Egeler RM, Schilham MW, Hogendoorn PC, Lankester AC.
    J Pathol; 2011 Feb 22; 223(3):347-57. PubMed ID: 21171080
    [Abstract] [Full Text] [Related]

  • 56. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
    Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y, Matsuki M, Matsuoka Y, Ghosh S, Kitano H, Nomoto K, Matsui J, Funahashi Y.
    PLoS One; 2019 Feb 22; 14(2):e0212513. PubMed ID: 30811474
    [Abstract] [Full Text] [Related]

  • 57. Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice.
    Ikeda A, Aoki N, Kido M, Iwamoto S, Nishiura H, Maruoka R, Chiba T, Watanabe N.
    Hepatology; 2014 Jul 22; 60(1):224-36. PubMed ID: 24700550
    [Abstract] [Full Text] [Related]

  • 58. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
    Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ.
    Cancer Treat Rev; 2018 Feb 22; 63():40-47. PubMed ID: 29207310
    [Abstract] [Full Text] [Related]

  • 59. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease.
    Menke J, Zeller GC, Kikawada E, Means TK, Huang XR, Lan HY, Lu B, Farber J, Luster AD, Kelley VR.
    J Am Soc Nephrol; 2008 Jun 22; 19(6):1177-89. PubMed ID: 18337479
    [Abstract] [Full Text] [Related]

  • 60. Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment.
    Cheng CC, Chang J, Ho AS, Sie ZL, Peng CL, Wang CL, Dev K, Chang CC.
    Cancer Immunol Immunother; 2024 Jul 02; 73(9):175. PubMed ID: 38953994
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 82.